Clinical Trial Search

Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…

Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05

Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…

Primary: Proportion of Patients Achieving an Investigator's Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA at Week 8. — 0.12…

Primary: Change in Epidermal Thickness — -31.66; -13.76; -28.65; -14.41 µm

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Number of Participants With Improved Skin Moisturization — 114 Participants

Primary: Incidence of Skin Irritation — 0 Participants

Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308

Primary: Heterozygous for Filaggrin (FLG) Null Mutations — 1; 4 participants

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT)…

Primary: Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24 — 74.6; 48.1; 68.5; 29.3 percentage of…

Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale

Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change

Primary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants

Primary: Eczema Area and Severity Index (EASI) Score on Day 43 - Change From Baseline — -4.97; -5.01 units on a scale — p=0.9416

Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale